CV Sciences Reports Q3 2025 Financial Results

CV Sciences ( (CVSI) ) just unveiled an update.

On November 13, 2025, CV Sciences reported its financial results for the third quarter of 2025, showing a revenue of $3.3 million, a decline from the previous year due to lower sales volume and regulatory challenges. Despite the revenue drop, the company maintained a healthy gross margin of 48.5% and introduced new products, aiming for organic growth and strategic M&A opportunities to enhance revenue and shareholder value. The company also addressed recent legislative changes affecting the hemp industry, expressing disappointment but seeing an opportunity to influence future regulations.

Spark’s Take on CVSI Stock

According to Spark, TipRanks’ AI Analyst, CVSI is a Underperform.

CV Sciences is currently facing significant financial challenges, with declining revenues and negative profit margins. The technical analysis indicates a bearish trend, although the stock is oversold, which might suggest a potential rebound. Valuation metrics are weak due to negative earnings and no dividend yield. The earnings call provided some positive insights, such as improved gross margins and cost efficiencies, but these are overshadowed by ongoing revenue declines and regulatory challenges.

To see Spark’s full report on CVSI stock, click here.

More about CV Sciences

CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods, with a focus on hemp extracts and other science-backed natural ingredients. Their products, including the +PlusCBD brand, are sold through various channels and are prominent in the natural products market. The company also offers cannabinoid-free supplements and plant-based foods, with operations in the U.S. and Europe.

Average Trading Volume: 183,542

Technical Sentiment Signal: Strong Sell

Current Market Cap: $6.08M

See more insights into CVSI stock on TipRanks’ Stock Analysis page.